Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,609 | -20,161 | -15,624 | -10,339 | -4,530 |
| Depreciation Amortization | 21 | 94 | 66 | 43 | 21 |
| Accounts payable and accrued liabilities | 532 | -469 | 317 | 1,266 | 1,114 |
| Other Working Capital | 226 | -1,007 | 309 | -349 | 159 |
| Other Operating Activity | 102 | 3,077 | 1,085 | 459 | -585 |
| Operating Cash Flow | $-4,728 | $-18,465 | $-13,847 | $-8,921 | $-3,822 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $0 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -26 | -97 | -72 | -47 | -22 |
| Common Stock Issued | 430 | 28,940 | 12,364 | 4,910 | 2,419 |
| Other Financing Activity | 0 | -395 | -395 | 0 | 0 |
| Financing Cash Flow | $404 | $28,448 | $11,897 | $4,864 | $2,397 |
| Exchange Rate Effect | 25 | 474 | 376 | 370 | 110 |
| Beginning Cash Position | 20,874 | 10,418 | 10,418 | 10,418 | 10,418 |
| End Cash Position | 16,575 | 20,874 | 8,844 | 6,730 | 9,103 |
| Net Cash Flow | $-4,299 | $10,456 | $-1,574 | $-3,687 | $-1,315 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,728 | -18,465 | -13,847 | -8,921 | -3,822 |
| Free Cash Flow | -4,728 | -18,465 | -13,847 | -8,921 | -3,822 |